News
StromaCare has raised €1,500,000 for the development of a new oncology therapy based on the immuno-modulation of the tumor stroma using a monoclonal antibody.
This biotech company based in Lyon announces a fundraising of €1,500,000 from Sham Innovation Santé (Advised by Turenne Groupe), Kreaxi, and Crédit Agricole Création. Complete press release StromaCare
Amoéba: Austria recommends the approval of the biocontrol active substance for the European territory
AMOEBA (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces that AGES (Agentur für Gesundheit und...
Amolyt Pharma announces US IND Clearance for the Ongoing Clinical Trial of AZP-3601 in Patients with Hypoparathyroidism
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the ongoing AZP-3601...
Amolyt Pharma announces European Commission has granted Orphan drug designation to AZP-3601 for the treatment of Hypoparathyroidism
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the European Commission has granted Orphan Drug Designation (ODD) to AZP- 3601 for the treatment of hypoparathyroidism. Amolyt...
Amolyt Pharma selected for the French Tech 120 Program
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has been selected for the French Tech FT120, a support program for French late-stage startups by the French State....
Gustave Roussy and LXRepair announce a partnership for personalized radiotherapy of cancer
LXRepair, a pioneer in personalized radiotherapy with functional assays measuring DNA repair to predict treatment response, with a clinical proof-of-concept of radiotoxicity prediction in breast and prostate cancer, and Gustave Roussy, Europe's leading cancer center,...
Amolyt Pharma Announces $80 Million Series B Financing led by Sectoral Asset Management and Andera Partners
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has closed an $80 million Series B equity financing round. The financing was co-led by Sectoral Asset Management...
Amolyt Pharma to Host Key Opinion Leader Webinar and Discuss Results of Phase I Clinical Trial of AZP-3601 on Friday, October 1st at 10:00am ET
Amolyt Pharma, a global company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced that it will host a key opinion leader (KOL) webinar on AZP-3601, the Company’s lead product candidate for the potential treatment...
Amolyt Pharma Exercises Option to License Optimized Acromegaly Drug Candidate from PeptiDream as it Continues to Build its Rare Endocrine Pipeline.
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, and PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (“PeptiDream”)(Tokyo: 4587), today announced that Amolyt Pharma has...
Theranexus and Beyond Batten Disease Foundation (BBDF) win us Investigational New Drug (IND) approval to start clinical development of BBDF 101
Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases, and Beyond Batten Disease Foundation (BBDF), announce receipt of Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) to launch a Phase I/II...